Publisher： Adis International
ISSN： 1173-8324
Source： Inpharma, Vol.1, Iss.1454, 2004-01, pp. : 11-11
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Time to consider placebo effect in QOL studies in NSCLC?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 327, 2001-01 ,pp. :
Access to resources
Recommend
RRM1-based tailored chemotherapy for NSCLC?
Inpharma, Vol. 1, Iss. 1432-1433, 2004-01 ,pp. :
Which gemcitabine dosage schedule best in NSCLC?
Inpharma, Vol. 1, Iss. 1479, 2005-01 ,pp. :
Gemcitabine + vinorelbine: superior to platinum-based regimens in NSCLC?
Inpharma, Vol. 1, Iss. 1308, 2001-01 ,pp. :
Time to abandon `best supportive care' as a standard of care for NSCLC?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 283, 2000-01 ,pp. :